Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence ; volume:20 ; number:1 ; day:18 ; month:8 ; year:2021 ; pages:1-12 ; date:12.2021
Cardiovascular diabetology ; 20, Heft 1 (18.8.2021), 1-12, 12.2021
- Creator
-
Schechter, Meir
Melzer-Cohen, Cheli
Rozenberg, Aliza
Yanuv, Ilan
Chodick, Gabriel
Karasik, Avraham
Kosiborod, Mikhail
Mosenzon, Ofri
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-021-01362-y
- URN
-
urn:nbn:de:101:1-2021110608361614741116
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schechter, Meir
- Melzer-Cohen, Cheli
- Rozenberg, Aliza
- Yanuv, Ilan
- Chodick, Gabriel
- Karasik, Avraham
- Kosiborod, Mikhail
- Mosenzon, Ofri
- SpringerLink (Online service)
Other Objects (12)
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease